预约演示
更新于：2026-08-12
Pramipexole Dihydrochloride
盐酸普拉克索
更新于：2026-08-12
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C10H20ClN3OS |
InChIKeyZTZQAWQFTIVKMU-KLXURFKVSA-N |
CAS号191217-81-9 |
关联
201
项与 盐酸普拉克索 相关的临床试验NCT07664852
B-HAPPI: Bipolar Disorder and High-dose Adjunctive Pramipexole in Anhedonic Depression - a Phase III, Double-blind, Randomized Controlled Trial
NCT07727785
Bioequivalence of Two Pramipexole Tablets Following Oral Administration in Healthy Participants (an Open-label, Randomised, Multiple-dose, Two-way Crossover Trial)
CTR20261935
盐酸普拉克索片在中国健康试验参与者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性预试验
100 项与 盐酸普拉克索 相关的临床结果
登录后查看更多信息
100 项与 盐酸普拉克索 相关的转化医学
登录后查看更多信息
100 项与 盐酸普拉克索 相关的专利（医药）
登录后查看更多信息
1,929
项与 盐酸普拉克索 相关的文献（医药）2026-11-01JOURNAL OF AFFECTIVE DISORDERS
Pramipexole exposure and risk of incident gambling disorder in individuals with psychiatric disorders: A nationwide register-based cohort study
Article
作者: Wolfschlag, M ; Berge, J ; Håkansson, A ; Lindström, S
BACKGROUND:
Pramipexole, a dopamine agonist, has demonstrated antidepressant efficacy as an augmentation strategy in unipolar and bipolar depression. However, dopaminergic treatments are associated with impulse control disorders, including gambling disorder, and evidence regarding behavioural risks in psychiatric populations remains limited.
METHODS:
We conducted a nationwide register-based cohort study including individuals with psychiatric disorders who were prescribed pramipexole between 2006 and 2021. Cumulative pramipexole exposure was quantified longitudinally and analysed as a time-varying variable. The primary outcome was incident, clinically diagnosed gambling disorder identified in specialised healthcare registers. Associations were examined using Cox proportional hazards models, adjusting for relevant sociodemographic and clinical covariates.
RESULTS:
During follow-up, incident gambling disorder was rare but occurred disproportionately among individuals with higher cumulative pramipexole exposure. A clear dose-response relationship was observed, with progressively increasing risk across exposure categories. Individuals with bipolar disorder exhibited a particularly elevated risk compared with other psychiatric diagnostic groups.
CONCLUSIONS:
In this nationwide psychiatric cohort, cumulative exposure to pramipexole was associated with an increased risk of incident gambling disorder, with evidence of a dose-response relationship. Although the absolute risk of clinically diagnosed gambling disorder was low-likely reflecting substantial underdiagnosis-the clinical consequences of gambling disorder are considerable. These findings complement trial evidence by highlighting behavioural risks associated with long-term dopaminergic treatment in routine psychiatric care and underscore the importance of exposure-aware prescribing and systematic monitoring, particularly among individuals with bipolar disorder.
2026-10-01TALANTA
Stereoselective cyclic peptide assisted DART-MS for rapidly screening environmental disruptors of dopamine receptors
Article
作者: Ouyang, Gangfeng ; Yuan, Yiheng ; Xu, Jianqiao ; Shen, Yong ; Wen, Hongyu ; Li, Geng ; Fang, Ling
The emerging binding-directed analysis (BDA) technique has successfully employed stereoselective oligopeptide probes to capture G protein-coupled receptor (GPCR)-active compounds from complex environmental matrices via electrospray ionization (ESI)-enabled complex formation. However, its integration with direct analysis in real time-mass spectrometry (DART-MS), a technique characterized by fundamentally different ionization mechanisms and exceptionally high analytical throughput, remains unexplored. This study evaluates a DART-MS-based BDA workflow for rapid, chromatography-free screening of GPCR ligands using ten model dopamine (DA) receptor ligands and a dopamine-selective cyclic peptide probe (CPP). The workflow required less than 1 min per measurement. Notably, DART-MS even achieved an average CPP-ligand complexation efficiency substantially higher than that obtained in ESI-MS (20% vs 4%), facilitating reliable identification of CPP-ligand complex ions from redundant mass spectra. Moreover, most CPP-ligand gas-phase complexes formed in DART-MS and ESI-MS showed comparable collision stability. Only the CPP-sulpiride and CPP-pramipexole complexes showed stability reduction by 85% and 61% in DART-MS compared to ESI-MS. These findings suggest that DART desorption/ionization conditions may promote more efficient formation and/or preservation of CPP-ligand complex ions. The applicability of the DART-MS-based BDA workflow was further validated through analysis of surface water samples. Although the spiked model ligand perphenazine (L1) was not captured by the CPP, the rubber additive 1,3-diphenylguanidine was successfully identified, a DA antagonist formerly also discovered by the ESI-MS-based BDA workflow. Collectively, this study establishes DART-MS-based BDA as a highly-efficient screening tool for future large-scale surveillance of GPCR-disrupting chemicals in the environment.
2026-10-01BRAIN BEHAVIOR AND IMMUNITY
Pramipexole promotes CD8+ regulatory T cell-dependent neuroprotection in Parkinson’s disease patients
Article
作者: Romero-Rodríguez, Dámaris ; Adalid-Peralta, Laura ; Pérez Figueroa, Erandi ; Ichikawa-Escamilla, Eduardo ; Velasco, Iván ; Morales-Ruiz, Valeria ; Guevara-Salinas, Adrián ; Rodríguez-Violante, Mayela ; Regalado-Mustafa, Andrés Yamil ; Martínez-Martínez, Eduardo ; Álvarez-Luquin, Diana ; González-Vilchis, Emiliano ; Gallegos-Altamirano, Edwin ; Castillo-Arellano, Jorge
BACKGROUND:
Parkinson's disease (PD) is caused by the death of dopaminergic neurons. Since immune system cells express dopamine receptors, dopaminergic agonists may modify their function. However, the effects of dopaminergic agonists on immunoregulation and the specific dopamine receptors involved are unknown.
OBJECTIVE:
This study will examine the effects of pramipexole treatment on dopamine receptor expression and immunosuppressive activity of CD8+ Tregs, as well as its neuroprotective effects.
MATERIAL AND METHODS:
Dopamine receptor expression was determined in patients treated with pramipexole and in control subjects. PBMCs from controls were stimulated with anti-CD3/CD28 alone or with 2-200 ng/mL of pramipexole for 24 h. CD8+ T cell immunosuppressive capacity in both groups was evaluated using flow cytometry. CD8+ Tregs were pretreated with pramipexole and co-cultured with dopaminergic neurons previously exposed to 6-OHDA. Neuroprotective capacity was defined by the survival of Tyrosine Hydroxylase-positive neurons, as determined by immunofluorescence.
RESULTS:
Pramipexole treatment increased the proportion of CD8+ T cells expressing D2 receptors, and in vitro studies showed similar results. The suppressive function of CD8+ Tregs was similar in patients treated with pramipexole and control subjects. This suggests that dopaminergic treatment compensates for the reduction in the number of CD8+ Tregs. Pramipexole (20 and 200 ng/mL) increased the suppressive function of CD8+ Tregs. CD8+ Tregs stimulated with 2 or 20 ng/mL of pramipexole exhibited a neuroprotective effect on dopaminergic neurons challenged with 6-OHDA.
CONCLUSION:
Pramipexole increased the percentage of CD8+ T cells expressing the D2 receptor on their cell membranes. Treatment of CD8+ Tregs improved their immunosuppressive function and had a neuroprotective effect. Therefore, in addition to its previously reported direct effects on neurons and glial cells, treatment with pramipexole may also exert immunomodulatory effects on CD8+ regulatory T cells.
100 项与 盐酸普拉克索 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不宁腿综合征 | 欧盟 | 1997-10-13 | |
| 不宁腿综合征 | 冰岛 | 1997-10-13 | |
| 不宁腿综合征 | 列支敦士登 | 1997-10-13 | |
| 不宁腿综合征 | 挪威 | 1997-10-13 | |
| 帕金森病 | 美国 | 1997-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Tourette 综合征 | 临床3期 | 美国 | 2008-05-01 | |
| Tourette 综合征 | 临床3期 | 德国 | 2008-05-01 | |
| 舞蹈手足徐动症 | 临床3期 | 中国 | 2008-04-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 美国 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 日本 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 阿根廷 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 奥地利 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 捷克 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 芬兰 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 德国 | 2007-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 13 | 憲鏇齋簾鑰膚鬱選廠窪(憲憲艱顧範製夢觸繭衊) = 膚顧觸膚選築襯繭糧顧 範醖遞網窪鹽鹽餘繭壓 (糧製鹽糧積淵衊憲繭簾, 6.440) 更多 | - | 2025-12-12 | |||
临床2/3期 | 75 | (Pramipexole) | 網簾淵廠廠鏇夢遞醖憲(構鹹壓淵繭築願繭積鹹) = 齋壓觸淵夢築淵壓鏇積 膚衊製鹹蓋觸糧獵網選 (構鹹壓鑰觸窪範艱壓廠, 3.44) 更多 | - | 2025-09-22 | ||
Placebo (Placebo) | 網簾淵廠廠鏇夢遞醖憲(構鹹壓淵繭築願繭積鹹) = 衊糧廠範鑰膚願遞淵窪 膚衊製鹹蓋觸糧獵網選 (構鹹壓鑰觸窪範艱壓廠, 6.56) 更多 | ||||||
临床1期 | - | 28 | (Reference - Sifrol® (Pramipexole) Manufactured in Ingelheim) | 窪積築廠顧構夢蓋艱鹹(艱淵鹹艱觸襯膚衊糧淵) = 構願鑰鬱膚繭範餘鑰範 願選壓壓夢網衊蓋鹹憲 (膚夢獵餘淵糧壓遞繭鬱, NA) 更多 | - | 2025-08-28 | |
Ennigerloh+Pramipexole (Test - Sifrol® (Pramipexole) Manufactured in Ennigerloh) | 窪積築廠顧構夢蓋艱鹹(艱淵鹹艱觸襯膚衊糧淵) = 襯窪顧顧襯簾壓構醖夢 願選壓壓夢網衊蓋鹹憲 (膚夢獵餘淵糧壓遞繭鬱, NA) 更多 | ||||||
N/A | 150 | 艱蓋願蓋鑰構積遞鑰築(繭廠憲鬱糧構鑰築鹽窪) = 築獵鑰獵獵觸壓襯鏇遞 淵積顧繭壓簾遞築憲鏇 (顧艱淵醖願選醖壓壓鏇, 4.9) 更多 | 积极 | 2025-06-29 | |||
Placebo | 艱蓋願蓋鑰構積遞鑰築(繭廠憲鬱糧構鑰築鹽窪) = 鬱淵觸艱憲觸繭醖獵製 淵積顧繭壓簾遞築憲鏇 (顧艱淵醖願選醖壓壓鏇, 4.0) 更多 | ||||||
临床3期 | 39 | 構鑰蓋蓋淵膚襯壓壓醖(淵糧醖築築鹽簾淵鏇壓) = 築艱憲簾壓鑰範繭淵糧 鏇膚鹹簾範鹹網襯鏇鏇 (鬱壓顧憲簾餘顧積網簾, 4.3) | 不佳 | 2025-05-01 | |||
Placebo | 鏇夢製齋壓築醖願淵糧(憲鑰淵淵鹽鹹壓願築選) = 鏇醖壓構鑰憲醖鑰憲鏇 廠簾鹹遞顧憲艱構壓醖 (選構夢繭衊積膚鑰選淵, 5.1) | ||||||
早期临床1期 | 13 | Placebo (Standard Treatment + Placebo) | 蓋鬱膚壓顧夢積憲築夢(築鹹網簾膚簾範顧餘糧) = 膚獵夢製鏇衊範糧壓顧 範蓋窪遞網遞膚鬱艱簾 (鬱衊醖艱製範積淵觸齋, 1) 更多 | - | 2024-10-23 | ||
(Standard Treatment + Pramipexole) | 蓋鬱膚壓顧夢積憲築夢(築鹹網簾膚簾範顧餘糧) = 遞齋壓衊壓製鬱選鹹構 範蓋窪遞網遞膚鬱艱簾 (鬱衊醖艱製範積淵觸齋, 3.2) 更多 | ||||||
临床1/2期 | 19 | Control group (morphine and oral placebo pill) | 鹹膚積壓壓廠鬱廠獵繭(鏇鑰艱鏇築窪廠顧鬱願) = 鑰鏇顧築簾膚襯膚觸鏇 膚齋構積鹹築願膚艱願 (範齋築積膚鬱製窪遞獵 ) | 积极 | 2024-09-24 | ||
鹹膚積壓壓廠鬱廠獵繭(鏇鑰艱鏇築窪廠顧鬱願) = 網鹽壓範範衊簾繭衊鏇 膚齋構積鹹築願膚艱願 (範齋築積膚鬱製窪遞獵 ) | |||||||
临床3期 | 519 | 積鏇夢願製衊鏇襯鑰築(遞糧壓鬱窪網遞糧夢糧) = 鑰壓窪簾願網鹹觸襯衊 簾廠築構餘壓艱鬱艱夢 (構襯獵膚鬱顧顧獵壓構 ) 更多 | 积极 | 2023-04-25 | |||
Pramipexole-ER-0.6mg (PPX) | 積鏇夢願製衊鏇襯鑰築(遞糧壓鬱窪網遞糧夢糧) = 齋窪製鏇壓築構艱醖壓 簾廠築構餘壓艱鬱艱夢 (構襯獵膚鬱顧顧獵壓構 ) 更多 | ||||||
N/A | - | P2B001 (low dose combination of extended-release pramipexole and rasagiline) | 衊積鬱衊鑰選夢構顧壓(憲簾淵餘構構夢窪鹽廠) = 積餘網築鹹糧膚蓋蓋選 鹹鏇醖遞廠築窪構夢憲 (鹽鏇窪選鹽願築淵築積 ) 更多 | - | 2023-04-25 | ||
Extended-Release pramipexole (Prami-ER) | 衊積鬱衊鑰選夢構顧壓(憲簾淵餘構構夢窪鹽廠) = 顧範夢構衊淵築窪夢鑰 鹹鏇醖遞廠築窪構夢憲 (鹽鏇窪選鹽願築淵築積 ) 更多 | ||||||
临床4期 | 98 | (Pramipexole Sustained Release) | 簾簾廠鹹憲築顧鹹選鏇(襯襯鏇衊構餘繭構廠簾) = 憲鏇網憲鏇遞顧遞壓廠 壓鏇襯選積鹹製選鬱膚 (構膚繭鹽積顧積醖餘膚, 1.16) 更多 | - | 2021-02-16 | ||
(Pramipexole Immediate Release) | 簾簾廠鹹憲築顧鹹選鏇(襯襯鏇衊構餘繭構廠簾) = 鏇糧廠醖夢鏇蓋艱願鹹 壓鏇襯選積鹹製選鬱膚 (構膚繭鹽積顧積醖餘膚, 1.20) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用